


THIRD EDITION 

Essential Guide to Blood Groups

GEOFF DANIELS AND IMELDA BROMILOW



WILEY Blackwell

Essential Guide to Blood Groups

Essential Guide to Blood Groups

THIRD EDITION

Geoff Daniels, PhD, FRCPath

Consultant Clinical Scientist and Head of Diagnostics
IBGRL, Bristol Institute for Transfusion Services
NHS Blood and Transplant
Bristol, UK

Imelda Bromilow, MSc, CBiol

Scientific Consultant
Liverpool, UK

WILEY Blackwell

This edition first published 2014, © 2014 by John Wiley & Sons, Ltd

Registered Office

John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Offices

9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Daniels, Geoff, author.

Essential guide to blood groups / Geoff Daniels, Imelda Bromilow. – Third edition.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-118-68892-2 (pbk.)

I. Bromilow, Imelda, author. II. Title.

[DNLM: 1. Blood Group Antigens—Handbooks. WH 39]

QP91

612.1'1825—dc23

2013019571

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover image: Bubaone

Set in 9/12pt Palatino by SPi Publisher Services, Pondicherry, India

Contents

Abbreviations, x

1 An introduction to blood groups, 1

What is a blood group?, 1

Blood group antibodies, 3

Clinical importance of blood groups, 3

Biological importance of blood groups, 3

Blood group systems, 4

Blood group terminology and classification, 4

2 Techniques used in blood grouping, 8

Factors affecting antigen–antibody reactions, 8

 Temperature, 8

 Time and ionic strength, 9

 pH, 9

 Antigen density, 9

Stages of haemagglutination reactions, 10

Direct agglutination, 11

Indirect agglutination, 12

 Enzyme techniques, 12

 Antiglobulin tests, 14

Elution techniques, 18

Automation of test procedures, 19

Flow cytometry, 19

Molecular blood group genotyping, 21

3 The ABO blood groups, 22

Introduction, 22

ABO antigens, antibodies, and inheritance, 22

A₁ and A₂, 23

Antigen, phenotype, and gene frequencies, 24

ABO antibodies, 25

Importance of the ABO system to transfusion and transplantation medicine, 26

Biochemical nature of the ABO antigens, 27

Biosynthesis of the ABO antigens and ABO molecular genetics, 28

H, the precursor of A and B, 30

ABH secretion, 31

H-deficient red cells, 32

Further complexities, 32

Acquired changes, 33

Associations with disease and functional aspects, 34

4 The Rh blood group system, 35

Introduction – Rh, not rhesus, 35

Haplotypes, genotypes, and phenotypes, 36

Biochemistry and molecular genetics, 37

D antigen (RH1), 40

 Molecular basis of the D polymorphism, 40

 D variants, 41

 Clinical significance of anti-D, 42

 D testing, 44

C, c, E, and e antigens (RH2, RH4, RH3, RH5), 44

 Clinical significance of CcEe antibodies, 45

 Molecular basis of the C/c and E/e polymorphisms, 45

Other Rh antigens, 45

 Compound antigens: ce, Ce, CE, cE (RH6, RH7, RH22, RH27),
 and G (RH12), 46

 C^w, C^x, and MAR (RH8, RH9, RH51), 46

 VS and V (RH20, RH10), 46

Rh-deficient phenotypes – Rh_{null} and Rh_{mod'}, 47

Putative function of the Rh proteins and RhAG, 47

5 Other blood groups, 49

The Kell system, 49

 The Kell glycoprotein and the *KEL* gene, 49

 Kell system antigens, 50

 Kell system antibodies, 51

 K₀ phenotype, 51

 McLeod syndrome, McLeod phenotype, and Kx (XK1) antigen, 52

The Duffy system, 52

Fy^a (FY1) and Fy^b (FY2), 52Anti-Fy^a and -Fy^b, 53

Fy3 and Fy5, 53

The Duffy-glycoprotein, a receptor for chemokines, 53

Duffy and malaria, 54

The Kidd system, 54

Jk^a (JK1) and Jk^b (JK2); anti-Jk^a and -Jk^b, 54

Jk(a–b–) and Jk3, 55

The Kidd-glycoprotein is a urea transporter, 55

The MNS system, 56

M (MNS1) and N (MNS2); anti-M and -N, 56

S (MNS3) and s (MNS4); anti-S and -s, 56

S– s– U– phenotype and anti-U, 57

Other MNS antigens and antibodies, 57

The Diego system, 57

Band 3, the red cell anion exchanger, 57

Di^a (DI1) and Di^b (DI2); anti-Di^a and -Di^b, 58Wr^a (DI3) and Wr^b (DI4); anti-Wr^a and -Wr^b, 58

Other Diego-system antigens, 59

The Lewis System, 59

Some other blood group systems, 61

P1PK, 61

Lutheran, 61

Yt, 61

Xg, 61

Scianna, 61

Dombrock, 62

Colton, 62

Landsteiner–Wiener (LW), 62

Chido/Rodgers, 62

Gerbich, 62

Cromer, 63

Knops, 63

Indian, 63

I, 63

JR and Lan, 64

Vel, 64

Antigens that do not belong to a blood group system, 64

6 Clinical significance of blood group antibodies, 65

Antibody production and structure, 66

Factors affecting the clinical significance of antibodies, 69

Antibody specificity, 69

Haemolytic transfusion reactions (HTR), 71

Intravascular red cell destruction, 72

Extravascular red cell destruction, 72

Haemolytic disease of the fetus and newborn (HDFN), 73

Crossmatching for infants under 4 months old, 75

Autoantibodies, 77

Tests to assess the potential significance
of an antibody, 77

Decision-making for transfusion, 78

7 Blood grouping from DNA, 81

Fetal blood grouping, 81

Blood group typing of patients and donors, 82

Next generation sequencing, 84

The future of blood group serology, 84

8 Quality assurance in immunohaematology, 85

Achieving total quality, 85

Frequency and specificity of control material, 86

Quality requirements for safe transfusion practice, 88

Checklist of critical control points, 89

Laboratory errors, root cause analysis (RCA),
and corrective and preventive action (CAPA), 89

9 Trouble-shooting and problem-solving in the reference laboratory, 92

ABO grouping, 92

Rh grouping, 94

Problems in antibody screening, identification,
and crossmatching, 95

10 Frequently asked questions, 102

What is the difference between sensitivity and specificity and
how can these be determined?, 102

Why is anti-A,B no longer obligatory in ABO typing?, 102

Why are two anti-D reagents often recommended
for RhD typing?, 103

What is the importance of detecting D variant (weak D and partial D)
phenotypes?, 103

How do I control the results for antiglobulin testing?, 103

Why should RhD positive women be tested more than once during pregnancy?, 104	
How often should transfusion recipients be tested for the presence of antibodies?, 104	
How can passive anti-D be differentiated from anti-D due to alloimmunisation?, 104	
Why do we need to perform antibody screening?	
Isn't a crossmatch by IAT at 37°C enough to detect incompatible blood?, 105	
What is the incidence of alloimmunisation post-transfusion?, 105	
How do I determine and identify antibodies present in a sample?, 105	
What is a compound antibody?, 105	
How can the incidence of compatible donors for a recipient with multiple antibodies be calculated?, 106	
Why can't the droppers in bottles of reagents be used instead of a volumetric pipette?, 106	
What cells should be used when performing an antibody titration?, 107	
How are the results of titrations reported?, 107	
What is a Major Obstetric Haemorrhage?, 107	
What is 'Massive Transfusion'?, 107	
When group-specific blood is in short supply, how do I select the 'next best' for transfusion?, 108	
How are high-titre haemagglutinins classified?, 108	
What is an 'immediate spin' crossmatch?, 108	
What is an 'electronic crossmatch'?, 108	
Which patients are not eligible for electronic issue of blood?, 108	
What is 'bed-side' testing?, 109	
What are signs and symptoms of a suspected transfusion reaction?, 109	
What action should be taken in the event of a suspected transfusion reaction?, 109	
In haemovigilance, how should 'near-miss' events be characterised?, 109	
Recommended reading and web sites, 111	
Index, 113	

Abbreviations

2ME	2-mercaptoethanol
ADCC	antibody dependent cell-mediated cytotoxicity
AET	2-aminoethylisothiuronium bromide
AHG	anti-human globulin
AIHA	autoimmune haemolytic anaemia
AML	acute myeloid leukaemia
CAPA	corrective and preventive action
CGD	chronic granulomatous disease
CHAD	cold haemagglutinin disease
CLT	chemiluminescence test
CMV	cytomegalovirus
cv	co-efficient of variation
DAF	decay accelerating factor
DARC	Duffy antigen receptor for chemokines
DAT	direct antiglobulin test
DTT	dithiothreitol
EDTA	ethylenediaminetetraacetic acid
ETC	enzyme treated cells
FMH	feto-maternal haemorrhage
GP	glycophorin
GPI	glycosylphosphatidylinositol
HA	haemolytic anaemia
Hb	haemoglobin
HCT	haematocrit
HDFN	haemolytic disease of the fetus and newborn
HFA	high frequency antigen
HLA	human leucocyte antigen
HTR	haemolytic transfusion reaction
IAT	indirect antiglobulin test
ICAM	intercellular adhesion molecule
Ig	immunoglobulin

IL	interleukin
IS	immediate spin
ISBT	International Society of Blood Transfusion
IUT	intrauterine transfusion
LFA	low frequency antigen
LISS	low ionic strength saline
MAC	membrane attack complex
MCA	middle cerebral artery
MGSA	melanoma growth stimulatory activity
MMA	monocyte monolayer assay
NANA	N-acetylneuraminic acid
NISS	normal ionic strength saline
PBS	phosphate buffered saline
PCH	paroxysmal cold haemoglobinuria
PCR	polymerase chain reaction
PEG	polyethylene glycol
PNH	paroxysmal nocturnal haemoglobinuria
QA	quality assurance
QC	quality control
RBC	red blood cell
RCA	root cause analysis
SNP	single nucleotide polymorphism
SOP	standard operating procedure
TQM	total quality management
WAIHA	warm auto-immune haemolytic anaemia

